AstraZeneca reported first-half 2026 revenues of £30.7 billion, up 6 percent at constant exchange rates from the prior year, with full-year 2025 sales at $59 billion and a 2030 target of $80 billion. CEO Pascal Soriot stated the company must avoid falling behind and operate at “Chinese speed,” following a Wainua clinical trial failure. Sales growth has been led by oncology products according to multiple outlets.